Symbols

PHAR

Pharming Group·NASDAQ

--(--)

PHAR fundamentals

PHAR Q4 2025 Earnings

Pharming Group (PHAR) released its earnings on Mar 12, 2026: revenue was 106.50M (YoY +14.89%), missed estimates; EPS was 0.07 (YoY +40.00%), beat estimates.

Revenue / YoY

106.50M

+14.89%

EPS / YoY

0.07

+40.00%

Report date

Mar 12, 2026

PHAR Earnings Call Summary for Q4,2025

Revenue Growth: 27% YoY in 2025, driven by RUCONEST (26%) and Joenja (29%). 2026 guidance: $405-425 million (8-13% growth).
Joenja Momentum: 120 U.S. patients on therapy, 40 new diagnoses in 2025. 52 eligible for pediatric label, 80+ on early access globally.
Pipeline Progress: Leniolisib Phase II trials completed, napazimone pivotal study on track for 2027 readout. Japan Joenja NDA recommended for approval.
Financial Discipline: 2026 R&D investment >$60 million, operating expenses growth 6-8%. Gross margin expected to improve to 90%.
Key Catalysts: Joenja pediatric label, international launches, and pipeline data readouts in 2026-2027.

Earnings

EPS

Revenue

Revenue & Expenses

PHAR has released its 2025 Q4 earnings report, with revenue of 106.53M, reflecting a YoY change of 14.96%, and net profit of 5.33M, showing a YoY change of 86.36%. The Sankey diagram below clearly presents PHAR's revenue sources and cost distribution.

Key Indicators

Pharming Group (PHAR) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Pharming Group (PHAR)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Pharming Group (PHAR)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Pharming Group (PHAR)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown